Glooko announced that it entered into a global partnership with Hedia to integrate its technology into Glooko’s diabetes management platforms.

The companies aim to provide an interoperable solution that brings together connected care, remote patient monitoring and digital therapeutics. This combination could enhance access for those with type 1 and type 2 diabetes requiring bolus insulin dosing advice.

Palo Alto, California-based Glooko’s current platforms enable patients to share diabetes data with healthcare providers. That includes blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight.

By integrating the Hedia Diabetes Assistant, users can receive bolus insulin dosing advice. That enables personalized care, reducing the burden of manually calculating required doses. When used with connected insulin pens, this combination brings enhanced visibility for providers managing patients on multiple daily injection therapy.

“The robust clinical data supporting Hedia’s efficacy demonstrates this could be a viable alternative for patients who are not able to access insulin pumps,” said Glooko CEO Russ Johannesson. “This partnership shows how interoperability gives people with diabetes the optimal tools available to ease the management of their condition and enhance health outcomes such as the stability of blood glucose levels.”

Glooko said in a news release that the integration improves its remote patient monitoring and supports virtual consultations.

The companies plan to initially launch their integration in Europe in the fourth quarter of 2023 and the first quarter of 2024.

“Glooko has demonstrated their strength in these areas with multiple third-party certifications, and that’s a key driver behind our partnership,” added Hedia CEO Peter Lucas. “Hedia’s Class IIb medical device designation ensures that the best solutions are being provided to patients and their care teams.”